LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (Nasdaq: ALNY).
If you purchased or otherwise acquired Alnylam shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.
The investigation focuses on whether Alnylam and certain of its officers and/or directors violated federal securities laws. On September 7, 2017, the Company advised investors that it stopped giving doses of fitusiran, its experimental hemophilia treatment, to patients enrolled in the Company’s clinical studies, following the death of a patient who developed a blood clot. Following this news, Alnylam’s stock price dropped.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.